Arctic Securities is acting as financial advisor in relation to the rights issue in A1M Pharma AB (publ). A1M Pharma AB (publ) is referred to as “A1M Pharma” or “the Company”. Shareholders have pre-emptive rights to subscribe for units. Three (3) existing shares held on the record date of January 31 2019, entitles to one (1) unit consisting of twelve (12) new shares and four (4) warrants. Subscription price of SEK 10.20 per unit, corresponding to 0.85 SEK per share. The subscription period runs 6 February – 20 February 2019. One (1) warrant entitles to subscribe for one (1) new share in A1M Pharma at a subscription price of SEK 1.00 during the period from 7 October – 25 October 2019. At full utilization of warrants in October 2019, an additional SEK 27.7m can be added. The rights issue is secured up to 100 percent through subscription- and guarantee undertakings. Subscription commitments from the new CEO and board members etc. amounts to approximately 5.7 percent of the rights issue. Six long-term investors are included in a "top" guarantee, which refers to the space between 56 up to 100 percent, corresponding to SEK 31.0m. The remaining guarantors/underwriters are included in the space from subscription commitments up to 56 percent, corresponding to SEK 35.5m of the rights issue. Arctic arranged the underwriting consortium. A Swedish prospectus and subscription note will be available before the subscription period on A1M Pharma’s website, www.a1m.se and Arctic Securities website.